STOCK TITAN

[SCHEDULE 13G/A] SiTime Corporation SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Amendment No. 4 to Schedule 13G discloses that FMR LLC, a Delaware parent holding company, and its controlling person Abigail P. Johnson beneficially own 19,946,433 shares of Structure Therapeutics Inc. (CUSIP 86366E106), representing 11.6 % of the company’s outstanding common stock as of 30 June 2025.

  • Sole voting power: 19,946,433 shares
  • Sole dispositive power: 19,946,433 shares
  • Shared voting/dispositive power: 0
Johnson holds identical dispositive power but no direct voting power, reflecting her indirect control through FMR.

The filing, submitted under Rule 13d-1(b), classifies FMR as a “parent holding company / control person.” The certification states the position is not intended to influence control of the issuer. Exhibit 99 lists the relevant subsidiaries.

Crossing the 10 % threshold makes FMR a significant institutional shareholder; future changes in its position could meaningfully affect GPCR’s float, liquidity and perception among investors.

La modifica n. 4 al Schedule 13G rivela che FMR LLC, una società madre del Delaware, e la sua persona di controllo Abigail P. Johnson possiedono beneficiariamente 19.946.433 azioni di Structure Therapeutics Inc. (CUSIP 86366E106), rappresentando il 11,6% del capitale sociale ordinario in circolazione al 30 giugno 2025.

  • Potere di voto esclusivo: 19.946.433 azioni
  • Potere dispositive esclusivo: 19.946.433 azioni
  • Potere di voto/dispositivo condiviso: 0
Johnson detiene un potere dispositive identico ma nessun potere di voto diretto, riflettendo il suo controllo indiretto tramite FMR.

La dichiarazione, presentata ai sensi della Regola 13d-1(b), classifica FMR come “società madre / persona di controllo.” La certificazione afferma che la posizione non è intesa a influenzare il controllo dell’emittente. L’Exhibit 99 elenca le filiali rilevanti.

Superando la soglia del 10%, FMR diventa un azionista istituzionale significativo; eventuali variazioni future della sua posizione potrebbero influenzare in modo rilevante il flottante, la liquidità e la percezione tra gli investitori di GPCR.

La enmienda n.º 4 al Schedule 13G revela que FMR LLC, una empresa matriz de Delaware, y su persona controladora Abigail P. Johnson poseen beneficiosamente 19.946.433 acciones de Structure Therapeutics Inc. (CUSIP 86366E106), representando el 11,6 % del capital social común en circulación al 30 de junio de 2025.

  • Poder de voto exclusivo: 19.946.433 acciones
  • Poder dispositive exclusivo: 19.946.433 acciones
  • Poder de voto/dispositivo compartido: 0
Johnson tiene un poder dispositive idéntico pero sin poder de voto directo, reflejando su control indirecto a través de FMR.

La presentación, realizada bajo la Regla 13d-1(b), clasifica a FMR como “empresa matriz / persona controladora.” La certificación indica que la posición no pretende influir en el control del emisor. El Anexo 99 enumera las filiales relevantes.

Al superar el umbral del 10 %, FMR se convierte en un accionista institucional significativo; futuros cambios en su posición podrían afectar significativamente el flotante, la liquidez y la percepción entre los inversores de GPCR.

Schedule 13G의 수정안 4는 델라웨어 소재 모회사인 FMR LLC와 그 지배인 Abigail P. Johnson가 Structure Therapeutics Inc. (CUSIP 86366E106)의 19,946,433주를 실질적으로 보유하고 있으며, 이는 2025년 6월 30일 기준 회사 발행 보통주식의 11.6%에 해당함을 공개합니다.

  • 단독 의결권: 19,946,433주
  • 단독 처분권: 19,946,433주
  • 공동 의결권/처분권: 0
Johnson은 동일한 처분권을 보유하지만 직접적인 의결권은 없으며, 이는 FMR을 통한 간접 통제를 반영합니다.

이 제출서는 Rule 13d-1(b)에 따라 FMR을 “모회사 / 지배인”으로 분류합니다. 인증서에는 이 지위가 발행인의 통제에 영향을 주려는 의도가 아님을 명시합니다. Exhibit 99에는 관련 자회사가 나열되어 있습니다.

10% 임계치를 넘음으로써 FMR은 중요한 기관 투자자가 되며, 향후 지분 변동은 GPCR의 유동 주식 수, 유동성 및 투자자 인식에 중요한 영향을 미칠 수 있습니다.

L’amendement n° 4 au Schedule 13G révèle que FMR LLC, une société mère du Delaware, et sa personne de contrôle Abigail P. Johnson détiennent de manière bénéficiaire 19 946 433 actions de Structure Therapeutics Inc. (CUSIP 86366E106), représentant 11,6 % des actions ordinaires en circulation au 30 juin 2025.

  • Pouvoir de vote exclusif : 19 946 433 actions
  • Pouvoir discrétionnaire exclusif : 19 946 433 actions
  • Pouvoir de vote/discrétionnaire partagé : 0
Johnson détient un pouvoir discrétionnaire identique mais aucun pouvoir de vote direct, reflétant son contrôle indirect via FMR.

Le dépôt, soumis en vertu de la règle 13d-1(b), classe FMR comme une « société mère / personne de contrôle ». La certification précise que cette position n’a pas pour but d’influencer le contrôle de l’émetteur. L’Exhibit 99 énumère les filiales concernées.

En franchissant le seuil de 10 %, FMR devient un actionnaire institutionnel important ; les évolutions futures de sa position pourraient avoir un impact significatif sur le flottant, la liquidité et la perception de GPCR par les investisseurs.

Nachtrag Nr. 4 zum Schedule 13G offenbart, dass FMR LLC, eine Muttergesellschaft aus Delaware, und deren kontrollierende Person Abigail P. Johnson wirtschaftlich 19.946.433 Aktien von Structure Therapeutics Inc. (CUSIP 86366E106) besitzen, was zum 30. Juni 2025 11,6 % des ausstehenden Stammkapitals des Unternehmens entspricht.

  • Alleiniges Stimmrecht: 19.946.433 Aktien
  • Alleiniges Verfügungsrecht: 19.946.433 Aktien
  • Geteiltes Stimm-/Verfügungsrecht: 0
Johnson besitzt identische Verfügungsrechte, jedoch kein direktes Stimmrecht, was ihre indirekte Kontrolle über FMR widerspiegelt.

Die Einreichung, eingereicht gemäß Regel 13d-1(b), klassifiziert FMR als „Muttergesellschaft / Kontrollperson“. Die Bescheinigung erklärt, dass die Position nicht dazu bestimmt ist, die Kontrolle über den Emittenten zu beeinflussen. Anlage 99 listet die relevanten Tochtergesellschaften auf.

Durch das Überschreiten der 10-%-Schwelle wird FMR zu einem bedeutenden institutionellen Aktionär; künftige Änderungen der Beteiligung könnten den Streubesitz, die Liquidität und die Wahrnehmung von GPCR bei Investoren maßgeblich beeinflussen.

Positive
  • Strong institutional backing: FMR LLC’s 11.6 % stake indicates sizeable confidence from a leading asset manager.
  • Enhanced liquidity: Large passive ownership can support daily trading volumes and price stability.
Negative
  • Ownership concentration: One holder controls over 10 % of shares, posing potential influence risk if intent changes.

Insights

TL;DR: Fidelity’s FMR reports 11.6 % GPCR stake—informative but not immediately valuation-moving.

FMR’s 19.9 M-share holding confirms robust institutional interest in Structure Therapeutics. While no purchase or sale details are provided, disclosure above 10 % signals monitoring visibility; any subsequent changes must be reported promptly, offering investors a window into Fidelity’s conviction. The filing alone does not alter fundamentals, but reinforces liquidity support and potential passive voting influence.

TL;DR: New 13G/A flags concentrated ownership; governance impact limited for now.

Because the position is reported on Schedule 13G—not 13D—FMR certifies a passive intent, implying no immediate push for board or control changes. Abigail P. Johnson’s dispositive but non-voting stance aligns with Fidelity’s customary structure. Still, a single holder controlling >10 % can sway shareholder votes if stance shifts. Investors should track any conversion to 13D, which would indicate activist intent.

La modifica n. 4 al Schedule 13G rivela che FMR LLC, una società madre del Delaware, e la sua persona di controllo Abigail P. Johnson possiedono beneficiariamente 19.946.433 azioni di Structure Therapeutics Inc. (CUSIP 86366E106), rappresentando il 11,6% del capitale sociale ordinario in circolazione al 30 giugno 2025.

  • Potere di voto esclusivo: 19.946.433 azioni
  • Potere dispositive esclusivo: 19.946.433 azioni
  • Potere di voto/dispositivo condiviso: 0
Johnson detiene un potere dispositive identico ma nessun potere di voto diretto, riflettendo il suo controllo indiretto tramite FMR.

La dichiarazione, presentata ai sensi della Regola 13d-1(b), classifica FMR come “società madre / persona di controllo.” La certificazione afferma che la posizione non è intesa a influenzare il controllo dell’emittente. L’Exhibit 99 elenca le filiali rilevanti.

Superando la soglia del 10%, FMR diventa un azionista istituzionale significativo; eventuali variazioni future della sua posizione potrebbero influenzare in modo rilevante il flottante, la liquidità e la percezione tra gli investitori di GPCR.

La enmienda n.º 4 al Schedule 13G revela que FMR LLC, una empresa matriz de Delaware, y su persona controladora Abigail P. Johnson poseen beneficiosamente 19.946.433 acciones de Structure Therapeutics Inc. (CUSIP 86366E106), representando el 11,6 % del capital social común en circulación al 30 de junio de 2025.

  • Poder de voto exclusivo: 19.946.433 acciones
  • Poder dispositive exclusivo: 19.946.433 acciones
  • Poder de voto/dispositivo compartido: 0
Johnson tiene un poder dispositive idéntico pero sin poder de voto directo, reflejando su control indirecto a través de FMR.

La presentación, realizada bajo la Regla 13d-1(b), clasifica a FMR como “empresa matriz / persona controladora.” La certificación indica que la posición no pretende influir en el control del emisor. El Anexo 99 enumera las filiales relevantes.

Al superar el umbral del 10 %, FMR se convierte en un accionista institucional significativo; futuros cambios en su posición podrían afectar significativamente el flotante, la liquidez y la percepción entre los inversores de GPCR.

Schedule 13G의 수정안 4는 델라웨어 소재 모회사인 FMR LLC와 그 지배인 Abigail P. Johnson가 Structure Therapeutics Inc. (CUSIP 86366E106)의 19,946,433주를 실질적으로 보유하고 있으며, 이는 2025년 6월 30일 기준 회사 발행 보통주식의 11.6%에 해당함을 공개합니다.

  • 단독 의결권: 19,946,433주
  • 단독 처분권: 19,946,433주
  • 공동 의결권/처분권: 0
Johnson은 동일한 처분권을 보유하지만 직접적인 의결권은 없으며, 이는 FMR을 통한 간접 통제를 반영합니다.

이 제출서는 Rule 13d-1(b)에 따라 FMR을 “모회사 / 지배인”으로 분류합니다. 인증서에는 이 지위가 발행인의 통제에 영향을 주려는 의도가 아님을 명시합니다. Exhibit 99에는 관련 자회사가 나열되어 있습니다.

10% 임계치를 넘음으로써 FMR은 중요한 기관 투자자가 되며, 향후 지분 변동은 GPCR의 유동 주식 수, 유동성 및 투자자 인식에 중요한 영향을 미칠 수 있습니다.

L’amendement n° 4 au Schedule 13G révèle que FMR LLC, une société mère du Delaware, et sa personne de contrôle Abigail P. Johnson détiennent de manière bénéficiaire 19 946 433 actions de Structure Therapeutics Inc. (CUSIP 86366E106), représentant 11,6 % des actions ordinaires en circulation au 30 juin 2025.

  • Pouvoir de vote exclusif : 19 946 433 actions
  • Pouvoir discrétionnaire exclusif : 19 946 433 actions
  • Pouvoir de vote/discrétionnaire partagé : 0
Johnson détient un pouvoir discrétionnaire identique mais aucun pouvoir de vote direct, reflétant son contrôle indirect via FMR.

Le dépôt, soumis en vertu de la règle 13d-1(b), classe FMR comme une « société mère / personne de contrôle ». La certification précise que cette position n’a pas pour but d’influencer le contrôle de l’émetteur. L’Exhibit 99 énumère les filiales concernées.

En franchissant le seuil de 10 %, FMR devient un actionnaire institutionnel important ; les évolutions futures de sa position pourraient avoir un impact significatif sur le flottant, la liquidité et la perception de GPCR par les investisseurs.

Nachtrag Nr. 4 zum Schedule 13G offenbart, dass FMR LLC, eine Muttergesellschaft aus Delaware, und deren kontrollierende Person Abigail P. Johnson wirtschaftlich 19.946.433 Aktien von Structure Therapeutics Inc. (CUSIP 86366E106) besitzen, was zum 30. Juni 2025 11,6 % des ausstehenden Stammkapitals des Unternehmens entspricht.

  • Alleiniges Stimmrecht: 19.946.433 Aktien
  • Alleiniges Verfügungsrecht: 19.946.433 Aktien
  • Geteiltes Stimm-/Verfügungsrecht: 0
Johnson besitzt identische Verfügungsrechte, jedoch kein direktes Stimmrecht, was ihre indirekte Kontrolle über FMR widerspiegelt.

Die Einreichung, eingereicht gemäß Regel 13d-1(b), klassifiziert FMR als „Muttergesellschaft / Kontrollperson“. Die Bescheinigung erklärt, dass die Position nicht dazu bestimmt ist, die Kontrolle über den Emittenten zu beeinflussen. Anlage 99 listet die relevanten Tochtergesellschaften auf.

Durch das Überschreiten der 10-%-Schwelle wird FMR zu einem bedeutenden institutionellen Aktionär; künftige Änderungen der Beteiligung könnten den Streubesitz, die Liquidität und die Wahrnehmung von GPCR bei Investoren maßgeblich beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



FMR LLC
Signature:Richard Bourgelas
Name/Title:Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:08/05/2025
Abigail P. Johnson
Signature:Richard Bourgelas
Name/Title:Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.
Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many Structure Therapeutics (GPCR) shares does FMR LLC own?

19,946,433 common shares, according to the Schedule 13G/A.

What percentage of GPCR’s outstanding stock does this represent?

The filing states 11.6 % of the class.

Does FMR LLC have voting power over these shares?

Yes, it reports sole voting power over all 19.9 M shares.

Is FMR seeking control of Structure Therapeutics?

No. The Schedule 13G indicates a passive investment with no intent to influence control.

Who signed the filing on behalf of FMR and Abigail P. Johnson?

Authorized signatory Richard Bourgelas signed using powers of attorney dated 23 May 2023.
SITIME CORP

NASDAQ:SITM

SITM Rankings

SITM Latest News

SITM Latest SEC Filings

SITM Stock Data

5.09B
21.22M
16.7%
82.31%
5.55%
Semiconductors
Semiconductors & Related Devices
Link
United States
SANTA CLARA